Clinical trials: Small Cell Lung Carcinoma Extensive Disease
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Lung Cancer
S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00045162
- Testing
- cisplatin, etoposide, irinotecan hydrochloride
- Where
- 408 sites in United States, Canada
- Volunteers
- 671 people
- Sponsor
- SWOG Cancer Research Network
Small Cell Lung Cancer
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain.
- Trial name
- SEZanne (NCT07155174)
- Testing
- ABBV-706, Atezolizumab, Etoposide
- Where
- 70 sites in United States, Belgium and 11 more
- Volunteers
- 180 people
- Sponsor
- AbbVie
Lung Cancer
Nitrocamptothecin in Treating Patients With Advanced Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have…
- Trial name
- NCT00006082
- Testing
- rubitecan
- Where
- France
- Volunteers
- 38 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lung Cancer
Sunitinib Malate in Treating Patients With Small Cell Lung Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00953459
- Testing
- sunitinib malate, laboratory biomarker analysis, fludeoxyglucose F 18
- Where
- Netherlands
- Volunteers
- 9 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
SCLC, Extensive Stage
Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Small Cell Lung cancer (SCLC) is a highly aggressive tumor that accounts for about 15 percent of all lung cancer cases. SCLC disease progresses rapidly, and about 2/3 of the patients have extensive stage (ES-SCLC) at the time of…
- Trial name
- NCT04660097
- Testing
- Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
- Where
- 2 sites in China
- Volunteers
- 34 people
- Sponsor
- Henan Cancer Hospital
Extensive-stage Small-cell Lung Cancer
Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study
This is a single-arm, real-world study in Chinese patients with extensive stage small cell lung cancer. The purpose of this study was to evaluate Trilaciclib's protection against chemotherapy-induced bone marrow suppression, the…
- Trial name
- NCT05071703
- Testing
- Trilaciclib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Small Cell Lung Cancer
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
The purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the…
- Trial name
- NCT04924101
- Testing
- Pembrolizumab, MK-4830, Boserolimab
- Where
- 49 sites in United States, Austria and 9 more
- Volunteers
- 122 people
- Sponsor
- Merck Sharp & Dohme LLC
Small Cell Lung Cancer
Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer
The subjects are being asked to take part in the Phase I or Phase II portion of a research study of a new investigational drug, LBH589, in combination with chemotherapeutic agents, carboplatin with etoposide.
- Trial name
- NCT00958022
- Testing
- LBH589 and carboplatin with etoposide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Ahmad Tarhini
Extensive Disease, First-Line
Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED)
Randomised trial comparing standard chemotherapy with carboplatin and etoposide with a combination of topotecan and cisplatin in patients with inoperable lung cancer of small cell type.
- Conditions
- Extensive Disease, First-Line, Small Cell Lung Cancer
- Trial name
- NCT00812266
- Testing
- topotecan + cisplatin, Etoposide + carboplatin
- Where
- Denmark
- Volunteers
- 281 people
- Sponsor
- Danish Oncological Lung Cancer Group
Lung Cancer, Pulmonary Neoplasms
Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide
To demonstrate an increase in overall survival for patients with newly diagnosed extended stage small cell lung cancer when treated with SR48692 versus placebo, after an initial response (complete or partial response or stable)…
- Conditions
- Lung Cancer, Pulmonary Neoplasms, Small Cell Lung Cancer
- Trial name
- SESAME (NCT00290953)
- Testing
- SR48692
- Where
- 14 sites in Argentina, Australia and 12 more
- Volunteers
- 432 people
- Sponsor
- Sanofi
Extensive Stage Lung Small Cell Carcinoma
Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
This phase II trial tests the effect of tarlatamab in treating patients with small-cell lung cancer (SCLC) that has spread from where it first started to other parts of the body (extensive-stage).
- Trial name
- NCT07423585
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Asrar Alahmadi
Lung Cancer, Malignant Mesothelioma
Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Conditions
- Lung Cancer, Malignant Mesothelioma, Metastatic Cancer
- Trial name
- NCT00020124
- Testing
- doxorubicin hydrochloride
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Extensive Stage Small Cell Lung Cancer
A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC
This is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of HLX10+ Chemotherapy vs placebo+Chemotherapy in Previously Untreated Patients with Extensive Stage Small Cell…
- Trial name
- NCT04063163
- Testing
- HLX10, carboplatin and etoposide
- Where
- 5 sites in Georgia, Poland and 3 more
- Volunteers
- 585 people
- Sponsor
- Shanghai Henlius Biotech
Breast Cancer, Colorectal Cancer
Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
RATIONALE: Placing a gene into T cells may improve the body's ability to recognize cancer cells and build an immune response to fight cancer.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer
- Trial name
- NCT01212887
- Testing
- MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes, aldesleukin, cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Cancer Research UK
Lung Cancer
Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00087048
- Testing
- topotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Case Comprehensive Cancer Center
Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
This study is open to adults with extensive-stage small cell lung cancer. The purpose of this study is to find out how well people with this type of cancer tolerate taking study medicines called obrixtamig and pumitamig.
- Trial name
- NCT07843940
- Testing
- Obrixtamig, Pumitamig, Carboplatin
- Where
- 27 sites in United States, Australia and 8 more
- Volunteers
- 55 people
- Sponsor
- Boehringer Ingelheim
Small Cell Lung Cancer
Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer
The study seeks to assess the efficacy of veliparib (ABT-888) in combination with carboplatin and etoposide in participants with extensive disease small cell lung cancer (ED SCLC).
- Trial name
- NCT02289690
- Testing
- Veliparib, Carboplatin, Etoposide
- Where
- 62 sites in United States, Australia and 10 more
- Volunteers
- 221 people
- Sponsor
- AbbVie
Small Cell Lung Cancer Extensive Stage
Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy
This study intends to recruit ES-SCLC patients with response to standard first-line chemo-immunotherapy to assess the safety of receiving different doses of consolidative thoracic radiotherapy.
- Trial name
- NCT06187740
- Testing
- thoracic radiotherapy
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Fudan University
Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
This study is an open-label, multi-center, adaptive Phase 1/2 trial evaluating the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CAR-NK cell products in adults with relapsed or refractory small…
- Conditions
- Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, SCLC, Extensive Stage
- Trial name
- DART-NK-SCLC (NCT07480213)
- Testing
- EB-DART-NK01 (DLL3/CD56 CAR-NK cells), Lymphodepleting chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech